When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients

Ruth Bargal, Marsha Zeigler, Bassam Abu-Libdeh, Vivi Zuri, Hanna Mandel, Ziva Ben Neriah, Fiona Stewart, Nursel Elcioglu, Tareq Hindi, Martine Le Merrer, Gideon Bach, Annick Raas-Rothschild*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Mucolipidosis II (ML II) and Mucolipidosis type III (ML III) are autosomal recessive disorders of lysosomal hydrolases trafficking due to the deficiency of the multimeric enzyme, UDP-N-acetylglucosamine-1-phosphotransferase. The α/β subunits encoded by the GNPTA gene is the catalytic subunit of the enzyme while the gamma recognition subunit is encoded by the GNPTAG gene. We report the molecular analysis of GNPTA in 21 families with ML II and 3 families with ML III. The ML II mutant genotypes included three splice-site mutations [IVS1-2A > G; IVS17 + 1G > A; IVS18 + 1G > A] in seven Palestinian, Israeli Arab-Muslims, and Turkish patients; a two base pair deletion [c.3502_3delCT] in 11 patients from Israel, Turkey, and Ireland; two nonsense mutations [c.2533C > T (Q845X); c.3613C > T (R1205X)], in a Turkish and an Arab-Muslim patient from the Nablus area, respectively, and an insertion mutation [c.2916insT] in a patient from Nablus. The ML III mutant genotypes included a splice-site mutation [IVS17 + 6T > G] in two patients from Irish/Scottish origin who were compound heterozygous for a nonsense mutation [c.3565C > T (R1189X)] and the deletion mutation [c.3502_3delCT], respectively. The third ML III patient from France was compound heterozygous for a missense mutation [c.1196C > T] and the same deletion [c.3502_3delCT] found homozygous in 11 ML II patients. The 21 ML II patients were homozygous while the three ML III patients were compound heterozygous for mutations in GNPTA. The results of this study confirm that ML II or ML III phenotype is not due to the localization of the mutations, but rather to the severity of the mutations, ML II and ML III might be allelic, and ML III is genetically heterogeneous. We suggest that the diseases due to mutations in GNPTA represent a clinical continuum between ML III and ML II, and the classification of these diseases should be based on the age of onset, clinical symptoms, and severity.

Original languageEnglish
Pages (from-to)359-363
Number of pages5
JournalMolecular Genetics and Metabolism
Issue number4
StatePublished - Aug 2006
Externally publishedYes


  • Mucolipidosis II
  • Mucolipidosis III


Dive into the research topics of 'When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients'. Together they form a unique fingerprint.

Cite this